219 related articles for article (PubMed ID: 22161024)
21. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
22. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
[TBL] [Abstract][Full Text] [Related]
23. Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis.
Cerutti JM; Oler G; Michaluart P; Delcelo R; Beaty RM; Shoemaker J; Riggins GJ
Cancer Res; 2007 Aug; 67(16):7885-92. PubMed ID: 17699795
[TBL] [Abstract][Full Text] [Related]
24. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
25. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.
Xu B; Scognamiglio T; Cohen PR; Prasad ML; Hasanovic A; Tuttle RM; Katabi N; Ghossein RA
Hum Pathol; 2017 Jul; 65():133-139. PubMed ID: 28552827
[TBL] [Abstract][Full Text] [Related]
26. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma.
Zou M; Al-Baradie RS; Al-Hindi H; Farid NR; Shi Y
Br J Cancer; 2005 Nov; 93(11):1277-84. PubMed ID: 16265347
[TBL] [Abstract][Full Text] [Related]
27. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND.
Alzahrani AS; Xing M
Endocr Relat Cancer; 2013 Feb; 20(1):13-22. PubMed ID: 23132792
[TBL] [Abstract][Full Text] [Related]
28. Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas.
Rodrigues R; Roque L; Espadinha C; Pinto A; Domingues R; Dinis J; Catarino A; Pereira T; Leite V
Oncol Rep; 2007 Oct; 18(4):917-26. PubMed ID: 17786355
[TBL] [Abstract][Full Text] [Related]
29. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
30. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
Paulson L; Shindo M; Schuff K; Corless C
Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.
McKelvie PA; Chan F; Yu Y; Waring P; Gresshoff I; Farrell S; Williams RA
Pathology; 2013 Dec; 45(7):637-44. PubMed ID: 24247620
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up.
Ito Y; Kudo T; Kobayashi K; Miya A; Ichihara K; Miyauchi A
World J Surg; 2012 Jun; 36(6):1274-8. PubMed ID: 22270990
[TBL] [Abstract][Full Text] [Related]
33. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas.
Sancisi V; Nicoli D; Ragazzi M; Piana S; Ciarrocchi A
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1745-9. PubMed ID: 22740704
[TBL] [Abstract][Full Text] [Related]
34. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
[TBL] [Abstract][Full Text] [Related]
35. Vitamin D receptor and progesterone receptor protein and gene expression in papillary thyroid carcinomas: associations with histological features.
Yavropoulou MP; Panagiotou G; Topouridou K; Karayannopoulou G; Koletsa T; Zarampoukas T; Goropoulos A; Chatzaki E; Yovos JG; Pazaitou-Panayiotou K
J Endocrinol Invest; 2017 Dec; 40(12):1327-1335. PubMed ID: 28589382
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
37. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS
Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774
[TBL] [Abstract][Full Text] [Related]
38. Lack of PTC gene (ret proto-oncogene rearrangement) in human thyroid tumors.
Namba H; Yamashita S; Pei HC; Ishikawa N; Villadolid MC; Tominaga T; Kimura H; Tsuruta M; Yokoyama N; Izumi M
Endocrinol Jpn; 1991 Dec; 38(6):627-32. PubMed ID: 1823030
[TBL] [Abstract][Full Text] [Related]
39. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
40. Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma.
Selemetjev S; Savin S; Paunovic I; Tatic S; Cvejic D
J Cancer Res Ther; 2018; 14(Supplement):S114-S119. PubMed ID: 29578160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
